61 results about "Aging cell" patented technology

This invention discloses a fusion protein targeting the urokinase-type plasminogen activator receptor and its application in the field of anti-aging. The fusion protein is composed of a hepatocyte growth factor active domain and a humanized anti-uPAR single-domain antibody linked by a flexible linker peptide, and its specific amino acid sequence is SEQ ID NO:3. This fusion protein can specifically bind to uPAR, which is highly expressed on the surface of senescent cells, with intramolar affinity, achieving targeted delivery of the hepatocyte growth factor active domain. In vitro experiments have demonstrated that this protein can significantly reverse the aging phenotype of human fibroblasts, effectively reduce aging-related β-galactosidase activity, p16INK4a protein expression, and interleukin-6 secretion, and promote cell proliferation. In a rapidly aging mouse model, this protein can systematically improve age-related physiological functional decline. The fusion protein of this invention achieves specific targeting and efficient treatment of senescent cells, providing a new solution for the development of anti-aging drugs.

The present invention relates to the use of GRP78 and peptides similar thereto or nucleic acids encoding the same. The peptides or nucleic acids according to the present invention can increase the expression of biomarkers having reduced expression in senescent cells, and thus can be used to restore the function of muscle tissue that has decreased in function due to aging, etc.

The invention belongs to the technical field of biological medicines, and particularly relates to lipid nanoparticles as well as a preparation method and application thereof. The invention discloses a lipid nanoparticle. The material of the lipid nanoparticle comprises phospholipid and cholesterol. According to the invention, a lipid nano-carrier delivery system entrapped with apoptotic protein Bax is prepared through a microfluidic technology, and high encapsulation rate and stable delivery of protein drugs are realized. The nano-carrier delivery system capable of actively encapsulating the lipidosome realizes targeted delivery to senescent cells in vivo, so that senescent cell apoptosis is effectively induced, the proportion of senescent cells in tissues is reduced, and a new thought and means are provided for anti-aging treatment.

The application belongs to the technical field of functional polypeptides, and particularly relates to an active peptide for senescent cells and a preparation method thereof, wherein the active peptide is obtained by molecular docking simulation screening and optimization with a helical structure segment in an IL-6R protein combined with a gp130 protein as a polypeptide template; the active peptide after functional optimization contains an FF unit driving nano self-assembly, a GFLG unit capable of being specifically cut by a lysosome protease highly expressed in a microenvironment of senescent cells, and an RYFQKWEKLRNQ unit generating high affinity with an IL-6 / IL-6R / gp130 complex; the designed active peptide itself has anti-aging activity and can also be used for synergistic delivery of drugs, and has a broad application prospect.

The application belongs to the technical field of biological medicine, and particularly relates to an anti-aging ergothioneine composition for improving mitochondrial function and a preparation method thereof. The composition comprises the following components: ergothioneine, sea hao polysaccharide and entada extract. The ergothioneine has good mitochondrial targeted antioxidant activity, can up-regulate the expression of Sirt1 to activate PGC-1a, and promote mitochondrial biosynthesis; the sea hao polysaccharide is helpful to restore mitochondrial function, promote the generation of mitochondrial high-energy phosphoric compounds, improve cell activity and energy supply for regeneration, and can up-regulate the expression of key genes for mitochondrial biosynthesis and ATP synthase related genes. The entada extract can synergize with the ergothioneine and the sea hao polysaccharide, significantly down-regulate the expression of aging related proteins such as p53, p21 and p16 in cells, simultaneously inhibit the transcription of aging related genes, and has a good protective effect on aging cells.

The technology relates in part to compositions containing a cell penetrating peptide that can be used to selectively reduce a senescent cell population. The technology also relates to methods of treatment of ageing and ageing-associated diseases using a cell penetrating peptide to selectively reduce a senescent cell population.

The invention provides a linear or cyclic polypeptide and a derivative or analogue thereof, wherein the linear or cyclic polypeptide is used for mobilizing a stress-inducing protein (sestrin) from GATOR / mTOR to sMAC in a non-aging cell; the polypeptide comprises or consists of an amino acid sequence derived from a stress-inducing protein or a truncated sequence thereof. These polypeptides are useful in the treatment of conditions requiring immediate intervention, such as acute diseases, sepsis caused by pathogen infection, or anaphylaxis, such as allergic shock, as immunotherapeutic agents for the treatment of cancer, and for autoimmune diseases.

Senescent cells are implicated in aspects of age-related decline in health and may contribute to certain diseases. Embodiments include formulations and methods for promoting longevity and treating a senescence associated disease or disorder. Applicants present three distinct classes and multiple associated therapeutic molecules that can function alone or in combination with the other molecules. The classes include transcription regulators, lipid intermediates and microRNAs. Additional embodiments include methods of promoting longevity by administering GRAS substances.

Provided is the use of NKG2D-CD3 and NKG2D-CD16 cell adapter molecules in the removal of aging cells and the treatment of aging-cell-accumulation-related diseases, wherein the cell adapter molecules comprise an NKG2D extracellular domain, a connection segment, and a CD3 or CD16 binding domain. The death of aging cells having high expression of NKG2D ligand is efficiently induced by means of bridging aging cells and immune cells, and thus the cell adapter molecules of the present application can be used for removing aging cells expressing the NKG2D ligand and treating aging-related diseases.

The invention discloses a targeted multi-channel synergistic anti-aging composition as well as a preparation method and application thereof, and belongs to the technical field of functional foods and biological medicines. According to the composition disclosed by the invention, ginsenoside, a hawthorn polyphenol-chitosan phospholipid complex and spina date seed total saponins are taken as core active ingredients, and a specific Senlytics active ingredient and a natural mTOR inhibitor are compounded, so that the synergistic regulation of five anti-aging pathways, namely Sirtuins activation, mTOR inhibition, mitochondrial autophagy activation, CD38 inhibition and senescent cell removal, can be realized at the same time. The composition is natural in raw material source, high in safety and good in stability, can be prepared into various dosage forms such as capsules, solid beverages and oral liquid, is suitable for daily anti-aging and sub-health conditioning, and has wide application prospects in the fields of anti-aging health foods and biological medicines.

Compositions of matter, devices, and treatment protocols for reducing deleterious effects of senescent cells in a mammal. The invention provides extracorporeal devices capable of removing, in some cases selectively, senescence associated factors including small molecules, proteins, lipoproteins, as well as in some embodiments extracellular vesicles including exosomes, apoptotic bodies, or cellular released particles. Extracorporeal removal of senescent cell associated factors is performed to augment effects of senolytic therapy. Removal of senescence associated factors is performed to enhance efficacy of regenerative medicine interventions.

This invention discloses a mitochondrial-targeted nanomaterial for senescent cells and its application in anti-aging. The material is a nucleic acid aptamer-tetrahedral DNA, mainly assembled from four single-stranded DNA sequences, SEQ ID Nos. 1-4. Preparation involves first hybridizing the four single-stranded DNA sequences, then concentrating them to obtain aptamer-modified tetrahedra, which are then coupled with tannic acid (TA) via a Mann reaction in the presence of formaldehyde to obtain the Apt-tFNAs-TA complex. Finally, it is incubated with excess catechins to obtain the final delivery material, Apt-tFNAs@catechin-TA. This invention's material exhibits good biocompatibility and skin tissue compatibility, significantly improving uptake efficiency and mitochondrial localization ability in senescent cells. It can effectively deliver polyphenolic compounds such as catechins and protocatechuic acid, improving mitochondrial function and addressing the technical problems of low delivery efficiency of active ingredients and insufficient targeted enrichment in senescent cells.

This invention discloses *Bifidobacterium longum* with anti-aging functions and its applications, belonging to the field of microbial technology. The *Bifidobacterium longum* BBS 02 provided by this invention can promote cell vitality and proliferation, inhibit the high activity of β-galactosidase in senescent cells, and inhibit the high expression of the cyclin-dependent kinase inhibitor gene Cdkn1a, thereby achieving an anti-aging effect. The *Bifidobacterium longum* BBS 02 can be used to prepare edible nutrients or skin nutrients.

This invention proposes a nucleic acid aptamer that specifically binds to human senescent dermal fibroblasts (HDFs), along with its screening, identification, and application. Specific aptamers exhibiting high targeting specificity to human senescent HDFs were screened using Cell-SELEX technology. The three selected candidate aptamers showed binding rates of 57.5%, 86.2%, and 50.7% to senescent HDF cells within the same timeframe, respectively, demonstrating high specificity and targeted binding ability. Furthermore, the aptamer possesses potential for detecting, imaging, and regulating the function of senescent cells, successfully providing a new direction for targeted anti-aging interventions and therapeutic applications.

The invention discloses a p16-OSKM transgenic mouse model and a reprogramming senescence cell construction method and application, and belongs to the technical field of cell biology and regenerative medicine. According to the method, a p16-OSKM hybrid mouse capable of specifically inducing an OSKM factor in a p16 high expression cell is obtained on the basis of hybridization of a p16-Ink4a-CreERT2 transgenic mouse, a Rosa26-CAG-LSL-rtTA3-IRES-mKate2 transgenic mouse and a Col1a1-TRE-OSKM-IRES-mCherry transgenic mouse. The selective activation of the OSKM factor in senescent cells with high expression of p16 can be realized by adding doxycycline into primary embryo fibroblasts separated from the mouse under an in-vitro culture condition, so that the senescent cells enter a cell cycle again and recover division and multiplication capacities. The technology provides an accurate model platform for basic research, and can be used for aging mechanism exploration, cell fate regulation and control, chronic disease treatment, development and screening of anti-aging drugs and the like.

The application discloses an engineered exosome targeting human urokinase-type plasminogen activator receptor uPAR and a preparation method and application thereof. Firstly, a high-affinity anti-human uPAR single-domain antibody VHH is prepared; then, a human umbilical cord mesenchymal stem cell engineering cell line expressing a VHH-PTGFRN fusion protein is constructed, and the engineered exosome is prepared and purified by combining three-dimensional hypoxic culture, chemical induction and size-exclusion chromatography technology. The engineered exosome comprises four comparative samples, wherein the core sample Exo^(VHH / miR) can simultaneously display the anti-uPAR VHH on the membrane surface to realize targeted delivery and enrich miR-193b-3p in the chamber to realize gene silencing, and the synergistic effect of the two can efficiently remove the uPAR high-expression senescent cells and inhibit the senescence-associated secretory phenotype SASP. The engineered exosome has the advantages of standardized preparation process, high yield and high purity, strong targeting, excellent curative effect and good safety, and can be used for preparing a treatment preparation for anti-aging and aging-related diseases, and has important clinical application value.

A system can be used to determine properties of a wellbore treatment fluid. The system can include a rotational system defining an axis of rotation and an aging cell. The aging cell can be positioned in the rotational system to rotate about the axis of rotation. The aging cell can include a housing, a sensor shaft, and a sensor. The housing can define an interior region of the aging cell to receive a wellbore treatment fluid. The sensor shaft can be at an angle from the axis of rotation and can be coupled to the interior region to transmit electronic signals about the wellbore treatment fluid. The sensor can be positioned on the sensor shaft to detect the electronic signals while the aging cell rotates about the axis of rotation, and the electronic signals can be used to determine the properties of the wellbore treatment fluid.

The invention discloses an application of loperamide in preparation of a medicine for treating osteoporosis, and belongs to the field of development of new application of medicines. Loperamide has the effects of inhibiting aging, increasing osteogenic differentiation of bone marrow mesenchymal stem cells and preventing osteoporosis of aged and postmenopausal mice; meanwhile, at the cellular level, loperamide can reduce expression of senescence factors in mouse mesenchymal stem cells, promote senescence cell apoptosis and inhibit cell senescence; and a new choice is provided for the treatment of senescence-related osteoporosis drugs.

The invention belongs to the technical field of biological medicines, and discloses application of beta-elemonic acid or a derivative or pharmaceutically acceptable salt thereof in preparation of medicines for regulating cell senescence and preventing and / or treating senescence-related diseases, including application as a cell senescence regulator (especially a senescence cell scavenger), and application of beta-elemonic acid or a derivative or pharmaceutically acceptable salt thereof in preparation of medicines for regulating cell senescence and preventing and / or treating senescence-related diseases. The invention also relates to application of the compound in preparation of medicines for preventing and / or treating diseases (such as organ fibrosis diseases and metabolic diseases) driven by cell aging pathology. In-vivo and in-vitro experiments prove that beta-EA can significantly reduce the number of SA-beta-gal positive senescence cells and down-regulate the expression of a core senescence marker protein p21 no matter in an in-vitro cell model or in an in-vivo pathological tissue. The invention also proves that beta-EA can reverse the degree of cell fibrosis, inhibits the transcriptional activity of an epithelial-mesenchymal transition pathway, has remarkable anti-fibrosis activity, and can be applied to treatment of organ fibrosis and other senescence-driven diseases.

The present invention relates to an anti-aging composition containing a Magnolia officinalis extract or magnolol, honokiol and 4-O-methlyhonokiol compounds. The extract or compound restores mitochondrial functions of senescent cells, reduces damaged DNA in cells, and restores senescent cells to a youthful cell state, and thus can be effectively used as a multifunctional cosmetic composition, a pharmaceutical composition, or a health functional food for inhibiting aging.

The technical field of the application is a device for medical, oral or dental hygiene. The application discloses a hydrogel material and a preparation method and application thereof. The preparation method of the hydrogel material comprises: preparing a ZnSe / rGO heterojunction by a hydrothermal method through ZnSe and rGO, wherein the ZnSe is a semiconductor material zinc selenide, and the rGO is a conductor material reduced graphene oxide; and uniformly dispersing the ZnSe / rGO heterojunction in a GelMA matrix, and loading and fixing the ZnSe / rGO heterojunction on the GelMA to obtain a hydrogel material Z / r@G, wherein Z refers to ZnSe, r refers to rGO, and G refers to GelMA, and the GelMA is methacrylated gelatin. The application develops a preventive strategy capable of delaying or reducing cell aging, which can not only avoid the influence of excessive removal of aged cells on later bone repair, but also widely exert an anti-aging effect.

The application provides a use of Qixuekang in preparation of a medicine for improving aging. Experimental researches prove that Qixuekang can significantly improve natural aging of mice, improve the exercise capacity and muscle function of old mice, and Qixuekang can improve the mitochondrial membrane potential, increase the expression of mitochondrial neogenesis related genes and reduce the production of active oxygen, improve the mitochondrial function of replicative senescent cells, and further improve the replicative senescence state of the natural aging cell line 2BS.

The invention belongs to the technical field of cosmetics, and discloses a dual synergistic anti-aging and anti-inflammatory composition and application thereof. The composition disclosed by the invention is prepared from benzylidene dimethoxy dimethyl indanone and a radix pseudostellariae extract, the mass ratio of the benzylidene dimethoxy dimethyl indanone to the radix pseudostellariae extract is (1: 0.01) to (1: 500000). By combining the benzylidene dimethoxy dimethyl indanone and the radix pseudostellariae extract, extracellular matrix and senescent cell related secretion phenotypes can be effectively improved, cell damage and senescence caused by UVA and UVB can be improved, expression of collagen and elastin can be promoted, expression of matrix metalloproteinase can be inhibited, expression of proinflammatory factors can be inhibited, and the anti-aging effect can be achieved. And the compound shows good anti-aging and anti-inflammatory effects at a relatively low concentration.

The present invention provides: a product that revitalizes senescent cells or induces resistance to SASP to thereby inhibit senescence; and foods, cosmetics, pharmaceuticals and the like containing the product. Provided are: an anti-aging product having anti-aging activity and produced by macrophages stimulated with a lipopolysaccharide; and an anti-aging product, such as a food, a cosmetic, a skin care product, a supplement, a quasi-drug or a pharmaceutical product, comprising the anti-aging product. The invention also provides a manufacturing method of the anti-aging product.

The invention discloses an application of sciatin in preparation of a product for improving cell viability, resisting cell aging, resisting oxidation or inhibiting senescence-related secretory phenotype (SASP) inflammatory factors. According to the application disclosed by the invention, the anti-aging activity of the sciaflavone is evaluated by constructing an IMR-90 cell model for inducing aging by chemotherapy. Experimental results show that the vitality of senescent cells can be remarkably improved at the concentration of 10 mu M, and the enhancing effect is 40% or above. More importantly, the sciaflavones can significantly reduce the level of reactive oxygen species (ROS) in senescent cells, and the average inhibition level reaches 75.0%. Meanwhile, the sciaflavin has a regulating or inhibiting effect on secretion of SASP inflammatory factors IL-6 and IL-8 in senescent cells. The results jointly prove that the sciaflavones have the potential of relieving the cell senescence state and support the application of the sciaflavones in preparation of anti-aging products.

The present invention relates to the field of biomedicine. Disclosed are a molecule for targeting senescent cells to stimulate endogenous immunity and use thereof. The drug provided by the present invention can mediate the interaction between senescent cells and immune cells, enhance the endogenous immune function, and achieve the goals of effectively clearing senescent cells and ameliorating aging-related diseases. A class of functional molecules targeting immune sensitization of senescent cells is provided. One end of the molecule targets membrane molecules of senescent cells, and labels the surface of senescent cells with glutamic acid, so as to mediate "coupling" between endogenous immune cells and senescent cells, thereby promoting the adhesion and clearance of senescent cells by immune cells. The molecule can regulate the immune microenvironment of aging tissues, and effectively reduce the number of senescence-associated β-galactosidase-positive senescent cells, while reversing fibrosis and improving the natural aging phenotype.

The invention provides application of plant-derived miRNA in anti-aging, and belongs to the technical field of biological medicine and functional nucleic acid molecules. The miRNA disclosed by the invention is mul-miRNA-n16 (hereinafter referred to as mmn16) from mulberries, and the nucleotide sequence of the miRNA is shown as SEQ ID No: 1; experiments prove that the mmn16 and the simulant thereof can remarkably reduce the SA-beta-Gal positive proportion, inhibit expression of senescence-related genes such as p16, p21 and p53 and remarkably improve proliferation and migration capabilities of senescence cells in senescence models constructed by HFF-1 and 3T6, so that the mmn16 has a good anti-cell senescence effect; besides, in an animal model, the mmn16 can promote wound healing of skin tissues in the animal model, which prompts that the mmn16 also has anti-aging and functional recovery potentials on the tissue level; the invention fills the technical blank that mmn16 has no application in cell aging resistance, provides a new thought and method for developing plant-derived anti-aging miRNA, and has important medical and social values for the research of intervening the cell aging process.

The invention discloses application of deaminotyrosine in preparation of a medicine for delaying heart aging and treating and / or preventing senile heart diseases, and belongs to the technical field of medicines. Experiments prove that deaminotyrosine can effectively reduce senescent cell accumulation in senescent hearts and remarkably improve the diastolic function and stress reserve capacity of naturally senescent animals. The application provides a brand-new, effective and high-potential-safety drug treatment strategy for dealing with heart aging and related disease challenges caused by population aging, and has great social and economic values.

The present disclosure relates to a pharmaceutical composition for treating retinal diseases, including a mitochondria-targeting compound as an active ingredient, wherein according to one aspect, the compound or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same may specifically induce apoptosis of senescent cells, and thus be usefully applied for the effective prevention or treatment of aging-related diseases.

The invention discloses a construction method and application of a skin aging cell model, and belongs to the technical field of cell models. According to the method, the skin aging cell model can be constructed by culturing cells with a complete culture medium containing an artificial sweetening agent. According to the invention, saccharin is used as a chemical inducer for skin aging for the first time, the common sweetening agent widely used for low-sugar and sugar-free food has a biological effect of inducing skin aging for the first time, and the blank of the component in aging model research is filled. Experimental results show that only 24-hour saccharin treatment is needed for one time, and the induction effect can reach the level of 48-hour treatment of a classic H2O2 induction model. The invention not only provides a brand-new special research tool for revealing the unknown mechanism of the artificial sweetener in skin aging, but also provides a standardized and high-throughput in-vitro screening platform for evaluating the skin health risk under the background of sugar-free diet and developing related anti-aging components.